Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Impilo on the establishment of Impilo Healthcare
Mandate

Vinge advises Impilo on the establishment of Impilo Healthcare

July 01, 2025 Private Funds

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Healthcare. The fund will have EUR 320m in commitments.

Impilo is a Nordic investment company focused solely on investments in lower-mid market Nordic healthcare companies across the pharmaceuticals, MedTech, specialist pharma services and other healthcare and related services industries. Impilo has a well-diversified portfolio of healthcare investments and manages approximately EUR 2 billion of capital from leading international investors.

Vinges team consisted of Nils Unckel, Anton Sjökvist, Viktoria Wnuk and Isabelle Asserståhl.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

 Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

 Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025